Kentucky Retirement Systems Sells 78 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kentucky Retirement Systems cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,656 shares of the company’s stock after selling 78 shares during the quarter. Kentucky Retirement Systems’ holdings in IDEXX Laboratories were worth $2,338,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Suncoast Equity Management increased its holdings in shares of IDEXX Laboratories by 11.6% during the fourth quarter. Suncoast Equity Management now owns 1,524 shares of the company’s stock worth $630,000 after purchasing an additional 158 shares during the period. Tandem Investment Advisors Inc. bought a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $1,598,000. Flossbach Von Storch SE increased its holdings in shares of IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares during the period. Concurrent Investment Advisors LLC increased its holdings in shares of IDEXX Laboratories by 36.7% during the fourth quarter. Concurrent Investment Advisors LLC now owns 861 shares of the company’s stock worth $356,000 after purchasing an additional 231 shares during the period. Finally, Alberta Investment Management Corp increased its holdings in shares of IDEXX Laboratories by 25.3% during the fourth quarter. Alberta Investment Management Corp now owns 10,900 shares of the company’s stock worth $4,506,000 after purchasing an additional 2,200 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Finally, Bank of America lifted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $452.77 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market capitalization of $37.08 billion, a P/E ratio of 42.43, a P/E/G ratio of 3.41 and a beta of 1.37. The company’s 50 day moving average price is $431.92 and its two-hundred day moving average price is $452.40.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock worth $6,161,276 over the last quarter. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.